Suscribirse

Synergistic Effect of SARS-CoV-2 Infection and COVID-19 Vaccination on the Risk of Venous Thromboembolism - 18/03/25

Doi : 10.1016/j.amjmed.2024.07.022 
Kyung Hun Yoo, MD a, #, Sang Hwan Lee, MD a, #, Yongil Cho, MD, PhD a, d, , Yun Jin Kim, PhD b, Jun Gon Kim c, Tae Ho Lim, MD, PhD a, Hyunggoo Kang, MD, PhD a, Jaehoon Oh, MD, PhD a, Byuk Sung Ko, MD, PhD a, Juncheol Lee, MD, PhD a
a Department of Emergency Medicine, College of Medicine, Hanyang University, Seoul, Republic of Korea 
b Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, Republic of Korea 
c School of Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea 
d Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul, Republic of Korea 

Requests for reprints should be addressed to Yongil Cho, MD, PhD, Department of Emergency Medicine, College of Medicine, Hanyang University, Wangsimni-ro 222, Seongdong-gu, Seoul, 04763, Republic of Korea; Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Wangsimni-ro 222, Seongdong-gu, Seoul, 04763, Republic of Korea.Department of Emergency MedicineCollege of MedicineHanyang University, Wangsimni-ro 222, Seongdong-gu, Seoul, 04763, Republic of KoreaHanyang Institute of Bioscience and BiotechnologyHanyang UniversityWangsimni-ro 222, Seongdong-guSeoul04763Republic of Korea

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background

Previous studies have reported a greater risk of venous thromboembolism among patients infected with SARS-CoV-2 and those who received COVID-19 vaccination. Nevertheless, there is a lack of understanding regarding the interaction effect on the risk of venous thromboembolism occurrence between SARS-CoV-2 infection and COVID-19 vaccination.

Methods

This was a retrospective cohort study including adult patients with confirmed SARS-CoV-2 infection between October 2020 and September 2021. Patients with confirmed SARS-CoV-2 infection were selected and matched 1:1 by age and sex with individuals who were not infected during the same period. A Cox proportional hazards model was used to analyze the venous thromboembolism risk.

Results

The study included 422546 individuals who were divided into 4 groups; the interaction group defined by having SARS-CoV-2 infection within 90 days following COVID-19 vaccination, the infection group defined by no vaccination before 90 days of SARS-CoV-2 infection, the vaccination group defined by COVID-19 vaccination without SARS-CoV-2 infection, and the reference group defined by neither COVID-19 vaccination nor SARS-CoV-2 infection. The results showed that the adjusted hazard ratio (aHR) of the interaction group was 29.71 (95% confidence interval [CI], 22.95-38.47), while the aHRs of the infection group and the vaccination group were 6.66 (95% CI, 5.18-8.58) and 2.31 (95% CI, 1.78-3.00), respectively.

Conclusions

A synergistic effect on the risk of venous thromboembolism was suggested when individuals were infected with SARS-CoV-2 within 90 days following COVID-19 vaccination.

El texto completo de este artículo está disponible en PDF.

Keywords : COVID-19, SARS-CoV-2, Vaccination, Venous thromboembolism


Esquema


 Funding: This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI22C1553).
 Conflicts of Interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
 Role of the Funder/Sponsor: The Korea Health Industry Development Institute had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
 Authorship: KHY: Conceptualization, Methodology, Writing – original draft, Writing – review & editing. SHL: Conceptualization, Methodology, Writing – original draft. YC: Project administration, Conceptualization, Methodology, Supervision, Writing – review & editing. YJK: Methodology, Formal analysis, Data curation. JGK: Writing – original draft. THL: Writing – review & editing. HK: Writing – review & editing. JO: Writing – review & editing. BSK: Writing – review & editing. JL: Writing – review & editing.


© 2024  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 138 - N° 4

P. 673 - avril 2025 Regresar al número
Artículo precedente Artículo precedente
  • Antibodies to Anaplasma phagocytophilum in Patients with Human Granulocytic Anaplasmosis Confirmed by Both Polymerase Chain Reaction and Culture
  • Gary P. Wormser, Lois Zentmaier, Dionysios Liveris, Ira Schwartz, Lindsey Schneider, Maria E. Aguero-Rosenfeld
| Artículo siguiente Artículo siguiente
  • Non-Invasive Brain Stimulation for Post-COVID-19 Conditions: A Systematic Review
  • Anna Markser, Jasper Vöckel, Alexa Schneider, Luise Baumeister-Lingens, Christine Sigrist, Julian Koenig

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.